Price T Rowe Associates Inc. MD Raises Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Price T Rowe Associates Inc. MD increased its holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 46.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 52,368 shares of the company’s stock after purchasing an additional 16,656 shares during the quarter. Price T Rowe Associates Inc. MD owned 0.10% of Fulcrum Therapeutics worth $247,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. Barclays PLC grew its holdings in Fulcrum Therapeutics by 367.1% in the 3rd quarter. Barclays PLC now owns 124,141 shares of the company’s stock worth $443,000 after acquiring an additional 97,565 shares during the last quarter. Matisse Capital grew its holdings in Fulcrum Therapeutics by 20.4% in the 4th quarter. Matisse Capital now owns 128,445 shares of the company’s stock worth $604,000 after acquiring an additional 21,728 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Fulcrum Therapeutics by 2.3% in the 4th quarter. Bank of New York Mellon Corp now owns 141,873 shares of the company’s stock worth $667,000 after acquiring an additional 3,126 shares during the last quarter. Bailard Inc. bought a new stake in Fulcrum Therapeutics in the 4th quarter worth $169,000. Finally, Connor Clark & Lunn Investment Management Ltd. grew its holdings in Fulcrum Therapeutics by 176.8% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 367,594 shares of the company’s stock worth $1,728,000 after acquiring an additional 234,810 shares during the last quarter. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Analyst Ratings Changes

FULC has been the topic of a number of recent analyst reports. HC Wainwright reissued a “neutral” rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a report on Wednesday, February 26th. Cantor Fitzgerald raised shares of Fulcrum Therapeutics from a “neutral” rating to an “overweight” rating and set a $10.00 price target on the stock in a report on Thursday. One analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, Fulcrum Therapeutics has an average rating of “Hold” and a consensus price target of $4.50.

Fulcrum Therapeutics Trading Up 4.2%

Shares of FULC opened at $6.88 on Friday. The firm’s 50-day moving average price is $3.69 and its 200-day moving average price is $3.79. The firm has a market capitalization of $371.38 million, a price-to-earnings ratio of -22.19 and a beta of 2.29. Fulcrum Therapeutics, Inc. has a 1-year low of $2.32 and a 1-year high of $10.13.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its earnings results on Thursday, May 1st. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.01. On average, research analysts forecast that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current fiscal year.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.